ADV6209

ADV6209 is an oral liquid solution developed by Advicenne for moderate sedation, originally developed in collaboration with the University Hospital of Amiens (CHU Amiens-Picardie).

This product has been specially designed for children to significantly reduce their anxiety and to improve their immobility when undertaking stressful or painful medical, therapeutic or diagnostic procedures. It is the only oral midazolam in liquid form suitable and indicated for children older than six months approved.

In March 2016, Advicenne sold ADV6209 to Primex Pharmaceuticals, a Swiss company, in a global deal worth tens of millions of euros. The sale entailed a significant upfront payment and subsequent milestones and royalties.

Marketing authorization for ADV6209 was granted on 12 September 2018.

Instead of micro pellet drugs, Advicenne uses liquid form drugs for people with swallowing difficulties, pharmacoresistant epileptic adults or children.

  Likozam®

Advicenne has been commercializing Likozam® (clobazam), an in-licensed medicine from Rosemont Pharmaceuticals, in France since June 2016.

This medicine is only available in France.

Under liquid form and indicated for children or people with swallowing difficulties, Likozam® product, is designed to treat partial and generalized chronic refractory epilepsy in children and adults.

  Levidcen®

Advicenne has been commercializing Levidcen® (levetiracetam), an in-licensed medicine from Desitin GmbH, in France since October 2015.

This medicine is only available in France.

Formulated with two-millimeter of levetiracetam micro pellet and tasteless, Levidcen® which is designed to treat patients with partial-onset seizures of epilepsy and suitable for both children and adults.
Advicenne's, company dedicated to developing and commercializing innovative treatments that address unmet medical needs in the area of nephrology.

Since its founding in 2007, Advicenne has been dedicated to developing and commercializing innovative treatments that address unmet medical needs in the area of nephrology. Our lead drug candidate, ADV7103, is in late-stage clinical trials for two indications: distal renal tubular acidosis (dRTA) and cystinuria. Listed on both the Euronext Paris and Euronext Brussels stock exchanges, the company is headquartered in Nîmes, France.

Contact Us

3 + 5 =

© 2019 Advicenne